DUBLIN--(BUSINESS WIRE)--Nov. 21, 2013--
plc (NYSE: MNK) today announced that its Board of Directors has set
Thursday, March 20, 2014 as the date for its annual general meeting of
shareholders. The meeting will be held at 3:00 pm, local time at the
Conrad Hilton Hotel, Earlsfort Terrace, Dublin 2, Ireland. Shareholders
of record at the close of business on January 10, 2014, are entitled to
receive notice of the meeting and will be eligible to vote.
Mallinckrodt is a global specialty pharmaceutical business that
develops, manufactures, markets and distributes specialty pharmaceutical
products and medical imaging agents. The company’s Specialty
Pharmaceuticals segment includes branded and generic drugs and active
pharmaceutical ingredients, and the Global Medical Imaging segment
includes contrast media and nuclear imaging agents. Mallinckrodt has
approximately 5,500 employees worldwide and commercial presence in
roughly 70 countries. The company’s 2013 revenue totalled $2.2 billion.
To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Lynn Phillips, 314-654-3263
Vice President, Investor Relations